GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (STU:4RY) » Definitions » Common Stock

Akeso (STU:4RY) Common Stock : €0.0 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Akeso Common Stock?

Akeso's quarterly common stock stayed the same from Jun. 2023 (€0.0 Mil) to Dec. 2023 (€0.0 Mil) and stayed the same from Dec. 2023 (€0.0 Mil) to Jun. 2024 (€0.0 Mil).

Akeso's annual common stock stayed the same from Dec. 2021 (€0.0 Mil) to Dec. 2022 (€0.0 Mil) and stayed the same from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€0.0 Mil).


Akeso Common Stock Historical Data

The historical data trend for Akeso's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Common Stock Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial - 0.01 0.01 0.01 0.01

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Akeso Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Akeso Business Description

Traded in Other Exchanges
Address
6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Akeso Headlines

No Headlines